Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block

Transfusion and Apheresis Science

Volumn 53, Issue 3, 2015, Pages 269-278

  Ruffatti, Amelia ^a   Favaro, Maria ^a   Brucato, Antonio ^b   Ramoni, Veronique ^c   Facchinetti, Myriam ^a   Tonello, Marta ^a   Del Ross, Teresa ^a   Calligaro, Antonia ^a   Hoxha, Ariela ^a   Grava, Chiara ^d   De Silvestro, Giustina ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Hospital of Bergamo   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d SAN MARTINO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY; STEROID;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; APHERESIS; AUTOIMMUNE DISEASE; COHORT ANALYSIS; CONGENITAL HEART BLOCK; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEART PACING; HEART RATE; HIGH RISK PATIENT; HUMAN; IMMUNOADSORPTION; PLASMAPHERESIS; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREGNANT WOMAN; PREVALENCE; REVIEW; STEROID THERAPY; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; FEMALE; HEART BLOCK; PLASMA EXCHANGE; PREGNANCY COMPLICATIONS; RISK FACTOR;

ANTIPHOSPHOLIPID SYNDROME; BLOOD COMPONENT REMOVAL; FEMALE; HEART BLOCK; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PLASMA EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS;

EID: 84983113634     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2015.11.006     Document Type: Review

References (62)

1. Hughes G.R. The Prosser-White oration 1983. Connective tissue disease and the skin. Clin Exp Dermatol 1984, 9:535-544.
2. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
3. Petri M. Hopkins Lupus Pregnancy Center: 1987 to 1996. Rheum Dis Clin North Am 1997, 23:1-13.
4. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174:1584-1589.
5. Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997, 314:253-257.
6. Franklin R.D., Kutteh W.H. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: a unique APA positive population. Hum Reprod 2002, 17:2981-2985.
7. Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408-413.
8. Laskin C.A., Spitzer K.A., Clark C.A., et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009, 36:279-287.
9. Mak A., Cheung M.W., Cheak A.A., et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 2010, 9:281-288.
10. Szodoray P., Bacskó G., Lakos G., et al. Combined therapy in pregnancy with primary antiphospholipid syndrome. Orv Hetil 2003, 1442411-1442413.
11. Chang P., Millar D., Tsang P., et al. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report. Am J Perinatol 2006, 23:125-129.
12. Kaaja R., Julkunen H., Ammälä P., et al. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 1993, 72:63-66.
13. Branch D.W., Peaceman A.M., Druzin M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000, 182:122-127.
14. Xiao J., Xiong J., Zhu F., et al. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Ther Med 2013, 5:287-291.
15. Bramham K., Thomas M., Nelson-Piercy C., et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011, 117:6948-6951.
16. Frampton G., Cameron J.S., Thom M., et al. Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet 1987, 2:1023-1024.
17. El-Haieg D.O., Zanati M.F., El-Foual F.M. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet 2007, 99:236-241.
18. Nakamura Y., Yoshida K., Itoh S., et al. Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies. Am J Reprod Immunol 1999, 41:307-311.
19. Kobayashi S., Tamura N., Tsuda H., et al. Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy. Ann Rheum Dis 1992, 51:399-401.
20. Ruffatti A., Marson P., Pengo V., et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 2007, 6:196-202.
21. Bortolati M., Marson P., Chiarelli S., et al. Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther Apher Dial 2009, 13:157-160.
22. Ruffatti A., Tonello M., Del Ross T., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006, 96:337-341.
23. Bramham K., Hunt B.J., Germain S., et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010, 19:58-64.
24. Fischer-Betz R., Specker C., Brinks R., et al. Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 2012, 21:1183-1189.
25. Ruffatti A., Tonello M., Cavazzana A., et al. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009, 123:482-487.
26. Simchen M.J., Dulitzki M., Rofe G., et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011, 90:1428-1433.
27. Danowski A., de Azevedo M.N., de Souza Papi J.A., et al. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009, 36:1195-1199.
28. Carmona F., Font J., Azulay M., et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001, 46:274-279.
29. De Carolis S., Botta A., Santucci S., et al. Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allerg Immunol 2010, 38:116-124.
30. Ruffatti A., Tonello M., Visentin M.S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology 2011, 50:1684-1689.
31. Ruffatti A., Salvan E., Del Ross T., et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost 2014, 112:727-735.
32. Bontadi A., Ruffatti A., Marson P., et al. Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J Clin Apher 2012, 27:200-204.
33. Ruffatti A., Olivieri S., Tonello M., et al. Influence of different IgG anticardiolipin antibody cut-offvalues on antiphospholipid syndrome classification. J Thromb Haemost 2008, 6:1693-1696.
34. Pengo V., Tripodi A., Reber G., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740.
35. Marson P., Bagatella P., Bortolati M., et al. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J Intern Med 2008, 264:201-203.
36. Yu Z., Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999, 340:227-228.
37. Gladman G., Silverman E.D., Yuk-Law, et al. Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies. Am J Perinatol 2002, 19:73-80.
38. Costedoat-Chalumeau N., Amoura Z., LupoglazoffJ.M., et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004, 50:3187-3194.
39. Tincani A., Rebaioli C.B., Frassi M., et al. Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome. Autoimmun Rev 2005, 4:423-428.
40. Villain E., Coastedoat-Chalumeau N., Marijon E., Boudjemline Y., Piette J.C., Bonnet D. Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status. J Am Coll Cardiol 2006, 48:1682-1687.
41. Costedoat-Chalumeau N., Amoura Z., Villain E., Cohen L., Piette J.C. Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res Ther 2005, 7:69-73.
42. Izmirly P.M., Saxena A., Kim M.Y., et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011, 124:1927-1935.
43. Buyon J.P., Hiebert R., Copel J., et al. Autoimmune associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998, 31:1658-1666.
44. Sonesson S.E., Salomonsson S., Jacobsson L.A., Bremme K., Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004, 50:1253-1261.
45. Rein A.J., Mevorach D., Perles Z., et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 2009, 119:1867-1872.
46. Skog A., Wahren-Herlenius M., Sundström B., Bremme K., Sonesson S.E. Outcome and growth of infants fetally exposed to heart block-associated maternal anti-Ro52/SSA autoantibodies. Pediatrics 2008, 1:e803-9.
47. Friedman D.M., Kim M.Y., Copel J.A., Llanos C., Davis C., Buyon J.P. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009, 103:1102-1106.
48. Eliasson H., Sonesson S.E., Sharland G., et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011, 124:1919-1926.
49. Cuneo B.F., Lee M., Roberson D., et al. A management strategy for fetal immune-mediated atrioventricular block. J Matern Fetal Neonatal Med 2010, 23:1400-1405.
50. Saleeb S., Copel J., Friedman D., Buyon J.P. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999, 42:2335-2345.
51. Ruffatti A., Favaro M., Cozzi F., et al. Anti-SSA/Ro-related congenital heart block in two family members of different generations [Letter]. Arthritis Rheum 2005, 52:1623-1625.
52. Friedman D.M., Llanos C., Izmirly P.M., et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010, 62:138-146.
53. David A.L., Ataullah I., Yates R., Sullivan I., Charles P., Williams D. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. Obstet Gynecol 2010, 116(Suppl. 2):543-547.
54. Brucato A., Ramoni V., Gerosa M., Pisoni M.P. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin [Letter]. Obstet Gynecol 2011, 117:177.
55. Ruffatti A., Milanesi O., Chiandetti L., et al. A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block?. Lupus 2012, 21:666-671.
56. Ruffatti A., Marson P., Svaluto-Moreolo G., et al. A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmun Rev 2013, 12:768-773.
57. Brucato A., Grava C., Bortolati M., et al. Congenital heart block not associated with anti-ro/la antibodies: comparison with anti-ro/la-positive cases. J Rheumatol 2009, 36:1744-1748.
58. Klauninger R., Skong A., Horvath L., et al. Serological follow-up of children born to mothers with Ro/SSA autoantibodies. Lupus 2009, 18:792-798.
59. Tonello M., Ruffatti A., Marson P., et al. Plasma exchange effectively removes 52-and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block. Transfusion 2015, Epub ahead of print.
60. Askanase A.D., Friedman D.M., Copel J., et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002, 11:145-151.
61. Izmirly P.M., Rivera T.L., Buyon J.P. Neonatal lupus syndromes. Rheum Dis Clin North Am 2007, 33:267-285.
62. Angelini A., Moreolo G.S., Ruffatti A., Milanesi O., Thiene G. Images in cardiovascular medicine. Calcification of the atrioventricular node in a fetus affected by congenital complete heart block. Circulation 2002, 105:1254-1255.